2. Search Result
Search Result
Results for "

paclitaxel cytotoxicity

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150231
    SU056
    2 Publications Verification

    		 YB-1 Cancer
    SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis, and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel (HY-B0015) .
    SU056
  • HY-401424
    Cremophor EL-36

    Polyoxyethylene(36) Castor Oil; PEG-36 Castor Oil

    		 Environmental Pollutants Biochemical Assay Reagents Others
    Cremophor EL-36 is a non-ionic surfactant, mainly used as a solubilizing carrier for poorly soluble Paclitaxel (HY-B0015). For example, Cremophor EL-36 can enhance the intracellular influx of Etoposide (HY-13629) without affecting drug efflux, and can dose-dependently increase the accumulation of VP-16 in lung adenocarcinoma cells (such as PC-14 and A549), significantly enhancing its cytotoxic effect .
    Cremophor EL-36
  • HY-125348
    6α-Hydroxy paclitaxel

    		Drug Metabolite Cancer
    6α-Hydroxy paclitaxel is one of the main metabolites of Paclitaxel (PTX) (HY-B0015), and it is generated by the liver cytochrome P450 enzyme CYP2C8. 6α-Hydroxy paclitaxel has bone marrow toxicity, but it can enhance the cytotoxicity of PTX against leukemia cells without causing cell toxicity. 6α-Hydroxy paclitaxel can be used in leukemia research .
    6α-Hydroxy paclitaxel
  • HY-173522
    KIF2C-IN-1

    		Kinesin Microtubule/Tubulin Cancer
    KIF2C-IN-1 is a cell-penetrating, selective KIF2C inhibitor with fluorescent properties (Ex/Em = 410/510 nm). KIF2C-IN-1 exhibits notable cytotoxicity and weak inhibitory effects on KIF2A/B. KIF2C-IN-1 prohibits the dissociation of KIF2C from microtubules. KIF2C-IN-1 inhibiting KIF2C reverses cross-resistance to microtubule-targeting agents. KIF2C-IN-1 reduces tumorigenesis in chemoresistant triple-negative breast cancer (TNBC) model in mice with the combination of Paclitaxel (HY-B0015) .
    KIF2C-IN-1
  • HY-125348S
    6α-Hydroxy Paclitaxel-d5

    		Isotope-Labeled Compounds Cancer
    6α-Hydroxy Paclitaxel-d5 is the deuterium labeled 6α-Hydroxy paclitaxel. 6α-Hydroxy paclitaxel is one of the main metabolites of Paclitaxel (PTX) (HY-B0015), and it is generated by the liver cytochrome P450 enzyme CYP2C8. 6α-Hydroxy paclitaxel has bone marrow toxicity, but it can enhance the cytotoxicity of PTX against leukemia cells without causing cell toxicity. 6α-Hydroxy paclitaxel can be used in leukemia research.
    6α-Hydroxy Paclitaxel-d5
  • HY-77572
    7-Epi 10-desacetyl paclitaxel

    7-epi-10-deacetyltaxol; 10-Deacetyl-7-epipaclitaxel

    		 ADC Payload Cancer
    7-Epi 10-desacetyl paclitaxel (7-epi-10-deacetyltaxol), a taxol derivative, exhibits cytotoxicity against HeLa cells with an IC50 of 85 μM .
    7-Epi 10-desacetyl paclitaxel
  • HY-N7256
    Dihydrocephalomannine

    		Microtubule/Tubulin Cancer
    Dihydrocephalomannine (compound 1b), an analogue of Paclitaxel, shows reduced cytotoxicity and tubulin binding compared to Paclitaxel .
    Dihydrocephalomannine
  • HY-N15194A
    Inostamycin A sodium

    		Bacterial Apoptosis Infection Cancer
    Inostamycin A sodium is an inhibitor of cytidine-5'-diphosphate-1,2-diacyl-sn-glycerol (CDP-DG):inositol transferase. Inostamycin A sodium reduces phosphatidylinositol turnover, and inhibits cell proliferation and transformation. Inostamycin A sodium inhibits cancer cell proliferation, induces apoptosis, and prevents tumor recurrence. Inostamycin A sodium exhibits antibacterial activity. Inostamycin A sodium is applicable to research related to infection and cancer .
    Inostamycin A sodium
  • HY-145491
    Resolvin D5

    		ERK NF-κB CCR Inflammation/Immunology
    Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatory T cell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis .
    Resolvin D5
  • HY-77572R
    7-Epi 10-desacetyl paclitaxel (Standard)

    7-epi-10-deacetyltaxol (Standard); 10-Deacetyl-7-epipaclitaxel (Standard)

    		 ADC Payload Reference Standards Cancer
    7-Epi 10-desacetyl paclitaxel (Standard) is the analytical standard of 7-Epi 10-desacetyl paclitaxel. This product is intended for research and analytical applications. 7-Epi 10-desacetyl paclitaxel (7-epi-10-deacetyltaxol), a taxol derivative, exhibits cytotoxicity against HeLa cells with an IC50 of 85 μM .
    7-Epi 10-desacetyl paclitaxel (Standard)
  • HY-177345
    SV119

    		Sigma Receptor Apoptosis Caspase Cancer
    SV119 is a selective sigma-2 (σ₂) receptor ligand (Ki ≈ 5-10 nM). SV119 induces apoptosis in various human cancer cell lines by activating caspase-3 and promoting mitochondrial depolarization. SV119 can enhance the effects of chemotherapeutic agents such as Paclitaxel (HY-B0015), increasing their cytotoxicity against tumor cells. SV119 significantly inhibits tumor growth in mouse xenograft models, both alone and in combination. SV119 is useful in the research of cancers such as breast, prostate, and pancreatic cancer .
    SV119
  • HY-139248
    Paclitaxel octadecanedioate

    		Drug Derivative Cancer
    Paclitaxel octadecanedioate (compound PTX-FA18) is comprised of Paclitaxel (HY-B0015) conjugated to 1,18-octadecanedioic acid (HY-W005178). Paclitaxel octadecanedioate mixed with human serum albumin (HAS) is cytotoxic to HT-1080, PANC-1, HT-29 and Hela cells (IC50s = 12, 2.48, 8.62, and 64.42 nM, respectively) .
    Paclitaxel octadecanedioate
  • HY-177482
    Pro-PTX

    		Drug Intermediate Neurological Disease Cancer
    Pro-PTX is a Pd-sensitive Paclitaxel (HY-B0015) prodrug with anticancer activity. Pro-PTX triggers intramolecular cyclization via Pd-catalyzed depropargylation to release active Paclitaxel (HY-B0015) and a non-toxic byproduct. Pro-PTX exhibits low cytotoxicity and antiproliferative activity in cancer cells and non-cancerous human cerebrovascular pericytes. Pro-PTX is applicable for research related to non-small cell lung cancer, glioblastoma and lung cancer .
    Pro-PTX
  • HY-N15297
    Isotenulin

    		P-glycoprotein Cancer
    Isotenulin inhibits the efflux function of P-glycoprotein by stimulation of P-glycoprotein ATPase, thereby overcoming the multidrug resistance (MDR) of cancer cells. Isotenulin exhibits cytotoxicity in multidrug-resistant cancer cell KB-vin and sensitive cancer cell HeLaS3. Isotenulin exhibits synergistic effect with Paclitaxel (HY-B0015), Vinblastine (HY-13780) and Doxorubicin (HY-15142) .
    Isotenulin
  • HY-144393
    P-gp/BCRP-IN-1

    		BCRP Cancer
    P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of P-gp and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel) .
    P-gp/BCRP-IN-1
  • HY-N19845
    2′,7-Diacetyltaxol

    		Drug Derivative Neurological Disease Cancer
    2′,7-Diacetyltaxol (Compound 3) is an acetylated derivative of Paclitaxel (HY-B0015) and a cytotoxic agent. 2′,7-Diacetyltaxol is isolated from the acetylated fraction of Taxus brevifolia Nutt. 2′,7-Diacetyltaxol exhibits anticancer activity against oral epidermoid carcinoma. 2′,7-Diacetyltaxol is applicable to the research of neurological diseases .
    2′,7-Diacetyltaxol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: